A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

A phase 1 clinical trial indicates that a vaccine may prevent pancreatic and colorectal cancer from coming back.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...